GlassScriptPhysician profile
Sharon Nancy Benson
NPI 1285958413
$12,110.82
in general payments reported to CMS, 2019-2025
63 companies · $2,652 in 2025
The $2,652 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,892 · 2022: $2,195 · 2023: $2,606 · 2024: $2,765 · 2025: $2,652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,500 · Education: $1,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,500.27 |
| Education | $1,522.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,050.99 | 2021-2025 | Padcev, Xospata, Vyloy |
| Seagen INC. | $981.60 | 2021-2025 | Padcev, Adcetris |
| Janssen Biotech, INC. | $817.79 | 2021-2025 | Rybrevant, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $733.27 | 2021-2025 | Calquence, Tagrisso, Epanova |
| Incyte Corporation | $503.01 | 2021-2025 | Jakafi, Pemazyre, Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $458.24 | 2021-2025 | Opdivo, Opdualag |
| Celgene Corporation | $418.95 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Novartis Pharmaceuticals Corporation | $411.72 | 2022-2025 | Kisqali |
| Pfizer INC. | $408.51 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $399.26 | 2022-2025 | |
| Abbvie INC. | $371.59 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $311.11 | 2022-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Daiichi Sankyo INC. | $280.80 | 2021-2025 | Enhertu, Datroway |
| Karyopharm Therapeutics INC. | $273.93 | 2022-2024 | Xpovio |
| Eisai INC. | $267.62 | 2021-2025 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $260.52 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Glaxosmithkline, LLC. | $254.46 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Emd Serono, INC. | $210.57 | 2022-2025 | |
| Stemline Therapeutics INC. | $161.25 | 2023-2024 | Orserdu |
| Alexion Pharmaceuticals, INC. | $159.81 | 2021-2025 | Ultomiris |
| Sobi, INC | $149.06 | 2025 | |
| Jazz Pharmaceuticals INC. | $144.56 | 2023-2025 | |
| Epizyme, INC. | $142.43 | 2021 | |
| Array Biopharma INC | $139.39 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Beigene USA, INC. | $138.78 | 2021-2024 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $137.99 | 2022-2025 | Libtayo |
| Sanofi-Aventis U.S. LLC | $132.99 | 2022-2023 | |
| Lilly USA, LLC | $132.36 | 2021-2025 | Verzenio, Jaypirca |
| Puma Biotechnology, INC. | $131.93 | 2021-2023 | |
| Gilead Sciences, INC. | $130.19 | 2022-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $117.84 | 2022-2025 | Fruzaqla, Ninlaro |
| Amgen INC. | $117.80 | 2021-2023 | Nplate, Xgeva, Vectibix |
| Ipsen Biopharmaceuticals, INC | $113.24 | 2022-2023 | Somatuline Depot, Onivyde |
| Genzyme Corporation | $110.61 | 2021-2025 | |
| Exelixis INC. | $109.56 | 2023-2025 | Cabometyx |
| Adc Therapeutics America, INC. | $108.51 | 2021-2025 | |
| Progenics Pharmaceuticals, INC. | $105.58 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $99.50 | 2023 | Quviviq |
| Mirati Therapeutics, INC. | $98.04 | 2023-2024 | Krazati |
| Genentech USA, INC. | $94.91 | 2021-2025 | Polivy, Venclexta |
| Aveo Pharmaceuticals, INC. | $91.07 | 2022-2024 | |
| Tempus Ai, INC | $76.10 | 2024-2025 | Xt Cdx |
| Servier Pharmaceuticals LLC | $74.28 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $73.75 | 2022-2024 | Pyrukynd |
| Pharmacyclics LLC, An Abbvie Company | $52.22 | 2022-2023 | Imbruvica |
| Alnylam Pharmaceuticals INC. | $48.77 | 2024-2025 | Givlaari |
| Morphosys, US INC. | $46.90 | 2022-2023 | Monjuvi |
| Myriad Genetic Laboratories, INC. | $44.91 | 2021-2023 | Myrisk |
| Cti Biopharma Corp. | $43.38 | 2022-2023 | Vonjo |
| Pharmaessentia USA Corporation | $42.54 | 2024-2025 | Besremi |
| Tactile Systems Technology INC | $40.07 | 2023-2025 | Nimbl, Flexitouch Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.81 | 2021-2022 | |
| Geron Corporation | $33.30 | 2025 | Rytelo |
| Taiho Oncology, INC. | $32.74 | 2025 | |
| Tg Therapeutics, INC. | $26.71 | 2021 | |
| Deciphera Pharmaceuticals INC. | $25.25 | 2024 | Qinlock |
| Recordati_rare_diseases_inc. | $25.11 | 2025 | Enjaymo |
| Fennec Pharmaceuticals, INC. | $24.99 | 2024 | Pedmark |
| Syndax Pharmaceuticals, INC. | $22.10 | 2025 | |
| Legend Biotech USA INC. | $16.48 | 2025 | Carvykti |
| Sumitomo Pharma America, INC. | $14.95 | 2025 | Orgovyx |
| G1 Therapeutics, INC. | $14.84 | 2023 | Cosela |
| Kite Pharma, INC. | $14.28 | 2025 | Yescarta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.